Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.05.9964PMID 16648493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer

  2006cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Parallel Detection of Transduced T Lymphocytes After Immunogene Therapy of Renal Cell Cancer by Flow Cytometry and Real-Time Polymerase Chain Reaction: Implications for Loss of Transgene Expression

  2005cited by this paper
• Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.

  2005cited by this paper
• Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

  2004cited by this paper
• A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

  2004cited by this paper
• Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.

  2004cited by this paper
• Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer

  2002cited by this paper
• Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250.

  1999cited by this paper
• Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.

  1999cited by this paper
• Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity.

  1996cited by this paper

• Next generation CAR-T cells to tackle down solid tumors.

  2026cites this paper
• CAR-engineered cell therapies: current understandings and future perspectives

  2026cites this paper
• The future unfolded: CAR T cells and the transformation of treatment algorithms in autoimmune neurology.

  2026cites this paper
• Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma

  2026cites this paper
• Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment—Implications for Therapy

  2026cites this paper
• Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma.

  2026cites this paper
• Targeting urological cancers with CAR-T cell therapy: current landscape and future directions.

  2026cites this paper
• Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy

  2025cites this paper
• Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming.

  2025cites this paper
• The potential of chimeric antigen receptor -T cell therapy for endocrine cancer

  2025cites this paper
• Complications of Chimeric Antigen Receptor T-cell Therapy.

  2025cites this paper
• The role of single cell transcriptomics for efficacy and toxicity profiling of chimeric antigen receptor (CAR) T cell therapies

  2025cites this paper
• Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy

  2025cites this paper
• Engineering sonogenetic EchoBack-CAR T cells.

  2025cites this paper
• Systemic delivery of cadherin 17-specific CAR T cells allows effective and safe targeting of colorectal cancer liver metastases.

  2025cites this paper
• Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives

  2025cites this paper
• CAR-T cell therapy: A therapeutic strategy for cancer treatment.

  2025cites this paper
• On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models

  2025cites this paper
• CD70-targeted allogeneic CAR T-cell therapy for clear cell renal cell carcinoma

  2025cites this paper
• Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors

  2025cites this paper
• The clinical toxicity of advanced therapy medicinal products

  2025cites this paper
• The discovery and development of tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma

  2025cites this paper
• Cell therapies for immune-mediated disorders

  2025cites this paper
• CAR-T cell therapy for cancer: current challenges and future directions

  2025cites this paper
• Engineering TME-gated inducible CAR-T cell therapy for solid tumors.

  2025cites this paper
• Reprogramming Immunity: Emerging Therapeutic Frontiers and Clinical Trial Advances of CAR-T Cell Therapy in Autoimmune Diseases

  2025cites this paper
• mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors

  2025cites this paper
• In vivo nano-engineering T cells for CAR-T therapy.

  2025cites this paper
• Leveraging T cells for cancer immunotherapy

  2025cites this paper
• Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma

  2025cites this paper
• Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

  2025cites this paper
• Optimizing CAR T cell therapy for solid tumours: a clinical perspective

  2025cites this paper
• Current landscape of CAR-therapy for osteosarcoma and rhabdomyosarcoma

  2025cites this paper
• Prospect of chimeric antigen receptor T-cell therapy for cancer

  2025cites this paper
• Frontiers in mechanobiology and mechanomedicine

  2025cites this paper
• CAR T cells in solid tumors and metastasis: paving the way forward

  2024cites this paper
• CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations

  2024cites this paper
• Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment

  2024cites this paper
• Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma

  2024cites this paper
• Boosting CAR-T cell therapy with CRISPR technology

  2024cites this paper
• CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?

  2024cites this paper
• iPS cell therapy 2.0: Preparing for next‐generation regenerative medicine

  2024cites this paper
• Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy

  2024cites this paper
• Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment.

  2024cites this paper
• Carbonic anhydrase IX: An atypical target for innovative therapies in cancer.

  2024cites this paper
• The heterogeneity of tumour-associated macrophages contributes to the clinical outcomes and indications for immune checkpoint blockade in colorectal cancer patients.

  2024cites this paper
• The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma

  2024cites this paper
• Development of chimeric antigen receptor (CAR)-T cells targeting A56 viral protein implanted by oncolytic virus

  2024cites this paper
• Evolution of cell therapy for renal cell carcinoma

  2024cites this paper
• TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer

  2024cites this paper
• Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control

  2024cites this paper
• Co-STARs combine the advantages of chimeric antigen and T-cell receptors for the treatment of tumors with low antigen densities

  2024cites this paper
• Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations

  2024cites this paper
• The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?

  2024cites this paper
• Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review

  2024cites this paper
• [The new generations of CAR-T cells].

  2024cites this paper
• Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials.

  2024cites this paper
• Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.

  2024cites this paper
• CAR-T cell therapy for breast cancer: Current status and future perspective.

  2024cites this paper
• Chimeric Antigen Receptor T-Cells (CAR T-Cells): An Engineered Targeted Therapy for Treatment of Cancer

  2024cites this paper
• Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity

  2024cites this paper
• The future of cellular therapy for the treatment of renal cell carcinoma

  2024cites this paper
• CAR T-cell therapy for gliomas

  2024cites this paper
• Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy

  2024cites this paper
• 100 years of the Warburg effect: A cancer metabolism endeavor.

  2024cites this paper
• Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy

  2024cites this paper
• Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects

  2024cites this paper
• CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY: HARNESSING EXTRACELLULAR VESICLES FOR ENHANCED EFFICACY.

  2024cites this paper
• CHIMERIC ANTIGEN RECEPTOR T CELLS: PAST, PRESENT, AND FUTURE

  2024cites this paper
• Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment

  2024cites this paper
• In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy

  2023cites this paper
• Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors.

  2023cites this paper
• CAR-T cells, the first pharmaceutical cell therapy.

  2023cites this paper
• Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies.

  2023cites this paper
• Validation of a High sensitivity assay for detection of CAR T cell vectors using low partition digital PCR technology.

  2023cites this paper
• Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice

  2023cites this paper
• Clinical Trials of Cellular Therapies in Solid Tumors

  2023cites this paper
• Current Advancements and Future Perspectives of Immunotherapy in Breast Cancer Treatment

  2023cites this paper
• Knowledge mapping and current trends of global research on CRISPR in the field of cancer

  2023cites this paper
• Current status of CAR-T cell therapy for pediatric hematologic malignancies

  2023cites this paper
• The Current Status and Future Perspectives of Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Endometrial Cancer

  2023cites this paper
• T cell immunotherapy for cervical cancer: challenges and opportunities

  2023cites this paper
• From bench to bedside: the history and progress of CAR T cell therapy

  2023cites this paper
• Challenges and optimal strategies of CAR T therapy for hematological malignancies.

  2023cites this paper
• CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens

  2023cites this paper
• Chimeric antigen receptor T cells therapy in solid tumors

  2023cites this paper
• Emerging Challenges to Cellular Therapy of Cancer.

  2023cites this paper
• Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy

  2023cites this paper
• Co-opting signalling molecules enables logic-gated control of CAR T cells

  2023cites this paper
• Application of CAR‐T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment

  2023cites this paper
• Conditional Control of Universal CAR T Cells by Cleavable OFF-Switch Adaptors

  2023cites this paper
• Living medicine: The story of the CAR T cell therapy

  2023cites this paper
• Building safety into CAR-T therapy

  2023cites this paper
• Targeting a cancer-specific LYPD3 glycoform for tumor therapy

  2023cites this paper
• Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

  2023cites this paper
• Injectable Supramolecular Hydrogels for In Situ Programming of Car‐T Cells toward Solid Tumor Immunotherapy

  2023cites this paper
• The landscape of cancer research and cancer care in China

  2023cites this paper
• Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities

  2023cites this paper
• Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy

  2023cites this paper
• CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review

  2023cites this paper